Novasep Acquires Bioprocess Development Specialist and Contract Manufacturer Henogen
News Jul 08, 2009
Novasep, a producer of active pharmaceutical ingredients (APIs) and purification technologies for the life science industries, announces today the acquisition of Henogen, a contract manufacturing organization (CMO) offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products.
The move adds a complementary, range of upstream processing capabilities and services to Novasep's comprehensive downstream processing (DSP) offer. Financial terms of the transaction were not disclosed.
As a result of this acquisition, Novasep customers will have access to manufacturing solutions covering almost every type of biopharmaceutical. In particular, Henogen brings its experience with an extensive array of expression tools including E. coli, yeast, L. lactis, insect and mammalian cells as well as viral vectors.
Novasep also becomes one of the few contract manufacturing organizations worldwide able to provide the complete manufacturing solution in the growing field of antibody-drug conjugates, covering early development to future commercial production.
Novasep now offers a combination of solutions for biopharmaceutical manufacturing. These include:
• Bioprocess development - both upstream and downstream processing
• An out-sourcing solution - contract biomanufacturing services, from the cell bank to the vial
• An in-sourcing solution - chromatography and membrane filtration technologies and complete DSP, from lab to industrial scale
"Novasep is making another strategic step forward with the acquisition of Henogen," said Dr Roger-Marc Nicoud, president & CEO of Groupe Novasep SAS. "The two companies have an excellent range of complementary capabilities and we look forward to offering our customers an even wider range of manufacturing services. The move is further confirmation of Novasep's determination to become a major player in the world biomanufacturing market."
"Joining Novasep will provide a boost to the development of our business worldwide," said Dr Jean-François Pollet, CEO of Henogen SA. "We believe the combined offer of our two companies will be very attractive to our existing and future customers."
The two companies have already cooperated on several biomanufacturing projects and together have a strong portfolio of customers including big pharma, mid-size pharma and biotechs. Henogen has more than 100 employee and operates two biomanufacturing facilities south of Brussels. It will become a part of Novasep Process, Novasep's biomolecules division.
Staphylococcus epidermidis is an ubiquitous colonizer of healthy human skin, but it is also a notorious source of serious nosocomial infections. Now, a new machine learning technique will help predict the risk of developing a serious, and possibly life-threatening S. epidermidis infection.READ MORE